Anavex Life Sciences (AVXL) 4.55 $AVXL Anavex Confirms

New Post Public Reply Private Reply Replies (0) Message Board

Nov 15, 2015 at 5:58 PM

Anavex Life Sciences (AVXL) 4.55 $AVXL

Anavex Confirms Data for Phase 2a Alzheimer's Trial for ANAVEX 2-73
GlobeNewswire - Wed Nov 11, 6:00AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(Nasdaq:AVXL) confirms the information in the November 9, 2015 press release announcing positive safety and cognitive efficacy data from the Phase 2a Alzheimer's trial for ANAVEX 2-73.
AVXL: 4.55 (-0.68)

Stocks Bottom Out at Session Lows on Rate Hike Talk
at The Street - Mon Nov 09, 1:32PM CST
Stocks bottom out at session lows by mid-afternoon Monday as expectations over when the Federal Reserve might hike rates shift.
AMZN: 642.35 (-23.25), TSLA: 207.19 (-5.75), NSC: 88.96 (+0.21), KSU: 87.45 (-0.27), XLY: 77.73 (-2.10), PCL: 46.19 (-0.34), CSX: 26.93 (-0.12), PCLN: 1,297.75 (-16.26), NFLX: 103.65 (-5.27), AVXL: 4.55 (-0.68), WY: 29.25 (-0.14), APA: 48.97 (+0.07), COST: 153.67 (-2.33), CP: 135.99 (-1.62), DF: 18.49 (-0.57), UNP: 83.78 (-0.17)

Stocks Extend Losses as Priceline Leads Consumer Losers
at The Street - Mon Nov 09, 10:09AM CST
Stocks extend losses by mid-morning Monday as Priceline is a laggard in the consumer sector.
BID: 29.01 (-1.00), AMZN: 642.35 (-23.25), TSLA: 207.19 (-5.75), HTZ: 15.89 (-0.04), XLY: 77.73 (-2.10), PCL: 46.19 (-0.34), PCLN: 1,297.75 (-16.26), DISH: 62.62 (-0.37), NFLX: 103.65 (-5.27), ERIC: 9.24 (-0.01), AVXL: 4.55 (-0.68), WY: 29.25 (-0.14), APA: 48.97 (+0.07), COST: 153.67 (-2.33), DF: 18.49 (-0.57), CSCO: 26.21 (-1.62)

Penny Stocks Alerts for Invo Bioscience, Dominovas Energy, Medical Marijuana, Global Equity, TapImmune, and Anavex Life Sciences
PR Newswire - Mon Nov 09, 8:00AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Invo Bioscience (OTCMKTS:IVOB), Dominovas Energy (OTCMKTS

NRG), Medical Marijuana (OTCMKTS:MJNA), Global Equity (OTCBB:GEQU), TapImmune (OTCMKTS:TPIV), and Anavex Life Sciences (OTCMKTS:AVXL).
AVXL: 4.55 (-0.68)

Anavex Presents Meaningless Results in Alzheimer's Drug Study
at The Street - Mon Nov 09, 7:53AM CST
"The chance you would have gotten similar data giving the patients 10 cups of coffee a day instead? Almost 100%," said Dr. Adam Kline, a researcher who reviewed the data.
BIIB: 284.84 (-6.49), AVXL: 4.55 (-0.68)

Anavex Announces Positive Primary and Secondary Endpoints Were Achieved in a Phase 2a Clinical Trial of ANAVEX 2-73 in Alzheimer's Diseaseâ??
GlobeNewswire - Mon Nov 09, 6:00AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(Nasdaq:AVXL). On Saturday, investigators presented positive safety and cognitive efficacy data for ANAVEX 2-73, the Company's lead investigational oral treatment for Alzheimer's disease targeting sigma-1 and muscarinic receptors, which are believed to reduce protein misfolding including reduction of beta amyloid, tau protein and inflammation at the international CTAD 2015 conference in Barcelona, Spain.
AVXL: 4.55 (-0.68)

Anavex Announces CTAD 2015 Abstract
GlobeNewswire - Thu Nov 05, 2:13PM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, is pleased to announce that the abstract for its presentation of full PART A data and preliminary PART B data from the ongoing Phase 2a clinical trial of ANAVEX 2-73 at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Barcelona, Spain on Saturday, November 7, 2015 is now available online.
AVXL: 4.55 (-0.68)

Why Anavex Life Sciences Shares Are Soaring 15% Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 02, 12:10PM CST
Image source: Avanex Life Sciences. What: After reporting last week that it has filed to uplist to the Nasdaq exchange and that it had inked a stock purchase deal with Lincoln Park Capital Fund, LLC worth up to $50 million, shares in Anavex Life...
AVXL: 4.55 (-0.68)

Penny Stocks Alerts for Urban Barns Foods, Buka Ventures, Hemp, GT Advanced Technologies, ANAVEX LIFE SCIENCES, and 3D EYE SOLUTIONS
PR Newswire - Mon Nov 02, 8:00AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Urban Barns Foods (OTCMKTS:URBF), Buka Ventures (OTCMKTS:NNRX), Hemp (OTCMKTS:HEMP), GT Advanced Technologies (OTCMKTS:GTATQ), ANAVEX LIFE SCIENCES (OTCMKTS:AVXLD), and 3D EYE SOLUTIONS (OTCMKTS:TDEY).
AVXL: 4.55 (-0.68)

Anavex Life Sciences Corp. (Nasdaq:AVXL) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Oct 29, 9:00AM CDT
What:
AVXL: 4.55 (-0.68), NDAQ: 56.59 (-1.12)

Anavex Commences Trading on NASDAQ Today - To Ring Friday's Closing Bell
GlobeNewswire - Wed Oct 28, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, is pleased to announce that it will begin trading its common stock on the NASDAQ Capital Market today at the opening of market hours under the symbol "AVXL."
AVXL: 4.55 (-0.68)

Anavex Announces Uplisting to NASDAQ
GlobeNewswire - Mon Oct 26, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the Company has received approval to begin trading its common stock on the NASDAQ Capital Market. Anavex's common stock will begin to trade on NASDAQ under the symbol "AVXL" at the opening of market hours on October 28, 2015.
AVXL: 4.55 (-0.68)

Military Researchers to Conduct Clinical Study of a "Skin Substitute" Using a Patient's Own Cells to Treat Complex Burns and Soft Tissue Injuries
PR Newswire - Tue Oct 13, 11:21AM CDT
Cooperative research and development efforts with the military, universities and the biotech industry can potentially lead to advancements in the treatment of severe wounds. Biotech companies with recent developments, partnerships and advancements in focus are Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), Array BioPharma, Inc. (NASDAQ: ARRY), Avanex Life Sciences Corp. (OTCQX: AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO), and Progenix Pharmaceuticals, Inc. (NASDAQ: PGNX)
PGNX: 6.71 (-0.03), AVXL: 4.55 (-0.68), JUNO: 50.00 (+0.11), ARRY: 4.40 (-0.19)

Anavex to Present at 4th Annual OktoberINVESTfest Conference
GlobeNewswire - Mon Oct 12, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(OTCQX:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 4th annual OktoberINVESTfest investors conference on Tuesday, October 13, 2015 at 2:30 p.m. ET. The Conference will be held at The New York Academy of Sciences in New York City.
AVXL: 4.55 (-0.68)

Anavex to Present Interim Phase 2a Clinical Trial Data of ANAVEX 2-73 at Late-Breaking Oral Session of CTAD 2015 Conference
GlobeNewswire - Wed Oct 07, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the presentation of full PART A data and preliminary PART B data from the ongoing Phase 2a clinical trial of ANAVEX 2-73 at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in Barcelona, Spain from November 5-7, 2015. The late-breaking oral session will be presented by the trial's Principal Investigator, Stephen Macfarlane, FRANZCP, Director and Associate Professor, Aged Psychiatry at Caulfield Hospital in Melbourne, Australia.
AVXL: 4.55 (-0.68)

Anavex to announce uplisting to Nasdaq & reverse stock split
M2 - Wed Oct 07, 3:11AM CDT
Biopharmaceutical company Anavex Life Sciences (OtherOTC:AVXL) revealed on Tuesday that it has submitted and finalised its application for the uplisting of its common stock to the NASDAQ Capital Market.
AVXL: 4.55 (-0.68)

CORRECTING and REPLACING -- Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split
GlobeNewswire - Tue Oct 06, 4:20PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it is finalizing an application to uplist trading of its common stock to the NASDAQ Capital Market. To meet the conditions of a NASDAQ listing, the Company announces a one-for-four (1-for-4) reverse stock split of its authorized, issued and outstanding common shares. The Company's common stock will begin trading on a post-split basis at the opening of trading on October 7, 2015.
AVXL: 4.55 (-0.68)

DUE DILIGENCE REPORT: Anavex Life Sciences Completes Enrollment for Clinical Phase 2a - BrokerBank Securities
PR Newswire - Tue Oct 06, 12:45PM CDT
Anavex Life Sciences Corp. (OTCQX: AVXL) shares closed at $1.90 yesterday, up 18.44%. Trading volume exceeded the 30 day average by a factor of three. The AVXL share price has been on a significant rise since July.
AVXL: 4.55 (-0.68)

Penny Stocks BUZZ for Hemp, Terra Tech, Medical Marijuana, NORTH AMERICAN CANNABIS HOLDINGS, Anavex Life Sciences, and Energizer Tennis
PR Newswire - Thu Oct 01, 8:00AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Hemp (OTCMKTS:HEMP), Terra Tech (OTCMKTS:TRTC), Medical Marijuana (OTCMKTS:MJNA), NORTH AMERICAN CANNABIS HOLDINGS (OTCMKTS:USMJ), Anavex Life Sciences (OTCMKTS:AVXL), and Energizer Tennis (OTCBB:EZRT).
AVXL: 4.55 (-0.68)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Endava's Stock Tumble Sparks Investor Class Action

A Rocky Day for Endava Investors Here's the thing, on September 21, 2026, Endava plc hit a rough patch that left a mark. After the market closed, the company announced that it had put its Chief Financial Officer, Mark Thurston, on administrative leave. This wasn't just a routine shuffle; it came on the heels of the Board's Audit Committee finding reason to probe into...

CorePower Yoga Expands in Miami with New Studios

Greasing the Wheels of Miami's Wellness Scene If you're living under a rock, you might not have noticed, but CorePower Yoga is making some serious moves in Miami. We're talking about two new studios opening their doors: one in Midtown Miami, already rolling out the mats as of October 19, and another flagship joint soon to hit Coral Gables. Clearly, they see the demand for...

Geothermal Energy Gets Boost with GRMS Adoption

Geothermal's Big Leap with the GRMS The oil and gas sector didn't explode overnight—it leapt due to a consistent, standardized language that spoke to investors like a charm. Now, the geothermal industry is borrowing a page from this book of success with the Geothermal Resources Management System (GRMS). Finally, a framework not just built on hope and hot air, but...

Call to Action: Make Disease Cure the Top Election Issue

A Call for Congressional Accountability The American Center for Cures is banging the drum for change, and they're banging it loud. Founded by Lou Weisbach, this group has come out swinging, urging Americans to slap disease onto the ballot in the midterms. Why? Because dealing with Alzheimer's, diabetes, heart disease, and cancer every year rips a whopping $1.1 trillion...

Norwegian Bella™: A New Era in Luxury Cruising

Setting Sail with Norwegian Bella™ in 2028 When you hear about another cruise ship hitting the water, eye rolls might come naturally. But Norwegian Cruise Line's latest announcement adds a few twists worth noting. Today, the big news is that the Norwegian Bella™, the freshest face in NCL's innovative Prima Class, is now open for bookings. This beauty will start its...

NSSF Battles NM's Unconstitutional Gun Law in Court

Taking Shots at New Mexico's Gun Laws You've got the National Shooting Sports Foundation (NSSF) heading back into the legal trenches. Fresh lawsuit filed, they're targeting New Mexico's Attorney General, Raúl Torrez, for trying to keep a seven-day "cooling off" period intact that they've already been told is unconstitutional. Look, this ain't their first rodeo with this...

Zika Virus: A Surprising Ally in Brain Cancer Fight

Here’s something you don’t hear every day: using a virus that typically targets the brain not as a foe, but as a formidable ally in the war against glioblastoma. It’s a gutsy play by UP Oncolytics, a scrappy biotech outfit cradled within Rosalind Franklin University’s Helix 51 incubator. Risky Bet on a Known Adversary Glioblastoma—a real beast in the cancer...

AI Agents Race: 10M Downloads Spark Competitive Fire

The AI Agent Arms Race is On Throwdown time in the AI jungle, folks. A new AI agent hit the big 10.9 million downloads in a mere six weeks. In the digital world, those kinds of numbers are the equivalent of finding a unicorn in your backyard. This data gem comes courtesy of Sensor Tower, as reported by Yahoo Finance, and it looks like the appetite for this technological...

Parents as Teachers Podcast: Anthem Awards Finalist

Celebrating Impact Through Parenthood Narratives Blending heartfelt stories with educational insights, the Parents as Teachers Podcast stands tall as a Finalist in two categories of the 6th Annual Anthem Awards. Recognizing achievements in Content & Media for both Education, Art & Culture and Health, this nod acknowledges the profound impact being made on family...

PrecisePK Celebrates 40 Years of Revolution in Dosing

Forty Years of Changing the Game There’s something to be said for sticking around in an industry for four decades. PrecisePK, a name that's become synonymous with precision dosing, has been revolutionizing how pharmacists do their jobs since 1985. This isn’t just a company resting on its laurels; it’s at the forefront of technological integration in healthcare....